2023Q1营收滑落43%,营业利润下滑80.3%,净利润下滑87%,这再次印证暴涨可持续的概率非常之低,需要非常谨慎对待。
目前市...查看全文
牛股小红书2022-03-29 13:46
$Eagle制药(EGRX)$ 宣布收购总部位于英国的Acacia Pharma Group(OTCPK代码:ACPGF)。
拟议交易条款将Acacia现有已发行和即将发行的股本估值为9470万欧元,即每股0.90欧元。
Eagle将以现金支付约7160万欧元,其余约2320万欧元预计将以Eagle普通股支付。Acacia Pharma股东将以0.68欧元现金...查看全文
用户48783635432019-05-08 11:21
【汇众医疗】$Eagle制药(EGRX)$ Eagle制药公司2019年第一季度保持增长,BENDEKA市场独占性得到保障,FDA延长BENDEKA专营权寿命,同时专利使用费提高;该公司第一季度总收入为4980万美元,基本每股净收益0.64美元,稀释后每股净收益0.62美元,调整后非GAAP基本每股净收益1.05美元。 查看全文https:/...查看全文
Pharmayang2018-05-12 04:10
$Eagle制药(EGRX)$ 这种股票拉起来也非常凶猛,和SUPN一样。这两个公司蛮有意思的,都有formulation的niche area。而且有比较固定的收入,相对而言风险小点。查看全文
Pharmayang2018-01-04 14:37
$Eagle制药(EGRX)$ 长期看好,这公司的pipeline不错,而且做的是比较简单的制剂改进,比如把粉末剂改成更加方便使用的注射液。而且这家公司盈利能力很强,财务报表非常好,在biotech里不常见,逢低买入。长线看好上90。查看全文
淘沙见金2017-11-02 19:38
$梯瓦制药(TEVA)$ 苦日子才刚刚开始。Copaxone这个季度收益跌了7%,下个季度还会跌更多。不过这个季度Bendaka收入倒是涨了20%,虽然对TEVA是杯水车薪,对 $Eagle制药(EGRX)$ 是好事。还是那句话,远离Teva,市场上比Teva好的投资机会多的是。查看全文
淘沙见金2017-08-04 03:36
$Eagle制药(EGRX)$ $梯瓦制药(TEVA)$ Treanda 和BendekaQ2的收益是$163MM, EGRX分到的收益应该在$39MM左右,如果其他产品收益在$13-$15MM,预计本季度的收益在$52MM-$54MM。查看全文
$Eagle Pharmaceuticals(EGRX)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2015-09-02 AccNo: 0001104659-15-063311 Size: 131 KB 网页链接
$Eagle Pharmaceuticals(EGRX)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2015-06-25 AccNo: 0001047469-15-005772 Size: 167 KB 网页链接
$Eagle Pharmaceuticals(EGRX)$ DEF 14A - Other definitive proxy statements Filed: 2015-06-25 AccNo: 0001047469-15-005770 Size: 729 KB 网页链接
$Eagle Pharmaceuticals(EGRX)$ 8-K/A [Amend] - Current report Filed: 2015-09-21 AccNo: 0001104659-15-066216 Size: 1 MBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Eagle Pharmaceuticals(EGRX)$ 8-K - Current report Filed: 2015-09-21 AccNo: 0001104659-15-066138 Size: 1 MBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Eagle Pharmaceuticals(EGRX)$ 8-K - Current report Filed: 2015-08-11 AccNo: 0001104659-15-058746 Size: 66 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接
$Eagle Pharmaceuticals(EGRX)$ 8-K - Current report Filed: 2015-08-10 AccNo: 0001104659-15-058274 Size: 331 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem 5.07: ...
$Eagle Pharmaceuticals(EGRX)$ 8-K - Current report Filed: 2015-08-11 AccNo: 0000827871-15-000038 Size: 308 KBItem 2.02: Results of Operations and Financial Condition 网页链接
$Eagle Pharmaceuticals(EGRX)$ 8-K - Current report Filed: 2015-07-23 AccNo: 0000827871-15-000035 Size: 150 KBItem 7.01: Regulation FD Disclosure 网页链接
$Eagle Pharmaceuticals(EGRX)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2015-08-11 AccNo: 0000827871-15-000042 Size: 3 MB 网页链接